{
    "nct_id": "NCT04940052",
    "official_title": "A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)",
    "inclusion_criteria": "* Signed informed consent must be obtained prior to performing any specific pre-screening and screening procedure\n* Male or female >= 18 years of age at the time of informed consent\n* Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid cancer\n* Radio active iodine refractory disease\n* BRAFV600E mutation positive tumor sample as per Novartis designated central laboratory result\n* Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapy\n* Eastern Cooperative Oncology Group performance status >= 2\n* At least one measurable lesion as defined by RECIST 1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Anaplastic or medullary carcinoma of the Tyroid\n* Previous treatment with BRAF inhibitor and/or MEK inhibitor\n* Concomitant RET Fusion Positive Thyroid cancer\n* Receipt of any type of small molecule kinase inhibitor within 2 weeks before randomization\n* Receipt of any type of cancer antibody or systemic chemotherapy within 4 weeks before randomization\n* Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization\n* A history or current evidence/risk of retinal vein occlusion or central serous retinopathy",
    "miscellaneous_criteria": ""
}